journal article·2025-07-18Open access

Time-Resolved Förster Resonance Energy Transfer Nanoassay Based on CdTe Quantum Dots for Sensitive Detection of Prostate Cancer Antigen 3

Catarina S. M. Martins, Anne Nsubuga, Nour Fayad, Ruifang Su, Thibault Gallavardin, Ihsan Çaha, Niko Hildebrandt, Francis Leonard Deepak, João A. V. Prior

ACS Applied Nano Materials· Volume 8· Issue 28

Abstract

Prostate Cancer Antigen 3 (PCA3) is a long noncoding RNA highly expressed in prostate cancer cells, making it a promising biomarker for noninvasive prostate cancer diagnosis. Simple and rapid detection using nanoprobes can potentially overcome the limitations of traditional diagnostic techniques. Here, we designed, characterized, and applied a DNA-strand displacement assay based on Förster Resonance Energy Transfer (FRET) between terbium (Tb) ions and semiconductor quantum dots (QDs) as a proof-of-concept for sensitive and specific mix-and-measure quantification of a synthetic DNA analogue of PCA3. The assay utilized QDs synthesized through an aqueous one-pot method. The time-resolved (TR) FRET assays achieved a detection limit of 0.65 nmol L –1 by using a SPARK benchtop fluorescence plate reader and 0.32 nmol L –1 by using a KRYPTOR Compact PLUS clinical plate reader. Despite slightly decreased performance, the TR-FRET nanoassay demonstrated reliable quantification of nanomolar PCA3 concentrations also in samples containing up to 50% of serum. These findings underscore the potential of Tb-to-QD FRET assays for rapid clinical prostate cancer diagnostics, offering a promising tool for the early detection of PCA3 in a noninvasive manner.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Quantum Dots Synthesis And Properties · Chalcogenide Semiconductor Thin Films · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

LAQV, REQUIMTE, Laboratory of Applied Chemistry, Department of Chemical Sciences

Faculty of Pharmacy of the University of Porto

International Iberian Nanotechnology Laboratory

Laboratoire COBRA

Université de Rouen Normandie, CNRS, INSA

Laboratory of Biomaging and Pathologies, UMR 7021 CNRS

University of Strasbourg

McMaster University

Department of Engineering Physics

Funding

Agence Nationale de la Recherche · European Regional Development Fund · Funda??o para a Ci?ncia e a Tecnologia · Canada Excellence Research Chairs, Government of Canada · Carnot Institute I2C

References (40)

Show source-provided references
1. 10.3322/caac.2183410.3322/caac.21834 ↗
2. ECIS, Prostate cancer burden in EU-27 . 2021. https://visitors-centre.jrc.ec.europa.eu/en/media/infographics/prostate-cancer-burden-eu-27 (Accessed 16/09/2024).
3. 10.1016/S0140-6736(24)00651-210.1016/S0140-6736(24)00651-2 ↗
4. 10.1177/175628722199718610.1177/1756287221997186 ↗
5. 10.1016/j.ajur.2018.11.00710.1016/j.ajur.2018.11.007 ↗
6. 10.1158/1078-0432.CCR-06-267910.1158/1078-0432.CCR-06-2679 ↗
7. Cornford P. · 2025
8. 10.1038/nrurol.2009.4010.1038/nrurol.2009.40 ↗
9. 10.3978/j.issn.1000-9604.2014.08.0810.3978/j.issn.1000-9604.2014.08.08 ↗
10. 10.1016/j.cca.2018.10.03610.1016/j.cca.2018.10.036 ↗
11. 10.1039/C9NR04864B10.1039/C9NR04864B ↗
12. 10.1016/j.snb.2017.05.03910.1016/j.snb.2017.05.039 ↗
13. 10.1021/acsami.9b1918010.1021/acsami.9b19180 ↗
14. 10.3390/eng401002210.3390/eng4010022 ↗
15. 10.1016/j.talanta.2020.12144410.1016/j.talanta.2020.121444 ↗
16. 10.1021/acs.analchem.9b0204010.1021/acs.analchem.9b02040 ↗
17. 10.1021/acssensors.6b0065110.1021/acssensors.6b00651 ↗
18. 10.1016/j.snb.2021.13058510.1016/j.snb.2021.130585 ↗
19. 10.1021/acssensors.2c0014910.1021/acssensors.2c00149 ↗
20. 10.1080/14737159.2019.164914410.1080/14737159.2019.1649144 ↗
21. 10.1021/acs.accounts.1c0069110.1021/acs.accounts.1c00691 ↗
22. 10.1016/j.trac.2020.11581910.1016/j.trac.2020.115819 ↗
23. 10.1021/acs.chemrev.6b0003010.1021/acs.chemrev.6b00030 ↗
24. 10.1021/ic401788310.1021/ic4017883 ↗
25. 10.1002/smll.20170033210.1002/smll.201700332 ↗
26. 10.1021/acsnano.5b0336410.1021/acsnano.5b03364 ↗
27. 10.3390/molecules2516367910.3390/molecules25163679 ↗
28. 10.1016/j.ccr.2013.08.03010.1016/j.ccr.2013.08.030 ↗
29. 10.3390/chemosensors1204007010.3390/chemosensors12040070 ↗
30. 10.1002/bio.319310.1002/bio.3193 ↗
31. 10.1021/cm034081k10.1021/cm034081k ↗
32. 10.1002/ejic.20230028810.1002/ejic.202300288 ↗
33. Medintz I. L. · 201310.1002/9783527656028 ↗
34. 10.1021/acsnano.8b0713710.1021/acsnano.8b07137 ↗
35. 10.1021/acs.analchem.2c0267310.1021/acs.analchem.2c02673 ↗
36. 10.1016/j.jallcom.2022.16650810.1016/j.jallcom.2022.166508 ↗
37. 10.1586/erm.10.12210.1586/erm.10.122 ↗
38. European Association of Urology, Guidelines on Prostate Cancer . 2025. https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation (Accessed 21–04–2025).
39. 10.1097/JU.000000000000349110.1097/JU.0000000000003491 ↗
40. 10.1097/JU.000000000000349210.1097/JU.0000000000003492 ↗